Imidapril

Hypertension is one of the chronic cardiovascular diseases with the largest number of patients worldwide, and the clinical demand for drugs with both antihypertensive efficacy and target organ protective effects continues to rise. Imidapril is a third-generation angiotensin-converting enzyme (ACE) inhibitor. It exerts a stable antihypertensive effect by inhibiting the activity of angiotensin-converting enzyme, reducing the production of angiotensin Ⅱ, and simultaneously inhibiting the degradation of bradykinin. Compared with similar drugs, it has a lower incidence of the adverse reaction of dry cough. In addition to patients with essential hypertension, it is also suitable for hypertensive patients complicated with diabetic nephropathy and left ventricular hypertrophy, and is currently one of the preferred options for long-term clinical management of hypertension.

In recent years, the domestic market size of antihypertensive drugs has been stable at the level of hundreds of billions of yuan, among which ACE inhibitors account for about 8% of the overall antihypertensive drug market. The original research of imidapril was developed by Mitsubishi Tanabe Pharma of Japan, and it entered the Chinese market around 2000. At present, there are 3 domestic generic drug manufacturers that have been approved, and the overall market competition pattern is relatively moderate. After the implementation of centralized drug procurement, the terminal price of imidapril has dropped by more than 60%, the clinical penetration rate has increased year by year, the compound annual growth rate of the market has remained at about 12% in the past three years, and the demand for API has also maintained a steady upward trend simultaneously.

CATO can provide a full set of imidapril impurity reference standards. All products meet the relevant regulatory requirements of the Chinese Pharmacopoeia and FDA, and are in sufficient stock. They can quickly respond to the quality control needs of pharmaceutical enterprises in the whole process of R&D, quality research and production, and ensure compliance and delivery efficiency.